November 21, 2016 - By Winifred Garcia · 0 Comments
Dipexium Pharmaceuticals (NASDAQ:DPRX) institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.54, from 1 in 2016Q1. The ratio increased, as 15 institutional investors opened new and increased positions, while 15 sold and decreased their equity positions in Dipexium Pharmaceuticals. The institutional investors in our partner’s database reported: 2.31 million shares, down from 2.73 million shares in 2016Q1. Also, the number of institutional investors holding Dipexium Pharmaceuticals in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 10 Increased: 11 New Position: 4.
Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The company has a market cap of $19.31 million. The Firm is focused on the development and commercialization of Locilex , a first-in-class, broad spectrum, topical antibiotic. It currently has negative earnings. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).
About 100 shares traded hands. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) has declined 82.07% since April 19, 2016 and is downtrending. It has underperformed by 85.93% the S&P500.
According to Zacks Investment Research, “Dipexium Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops and commercializes Locilex (TM), small peptide topical antibiotic for the treatment of certain mild and moderate skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds, and nasal colonization of methicillin-resistant staphylococcus aureus. Dipexium Pharmaceuticals, LLC is based in White Plains, New York.”
Kingdon Capital Management L.L.C. holds 0.53% of its portfolio in Dipexium Pharmaceuticals Inc for 970,124 shares. 683 Capital Management Llc owns 179,000 shares or 0.28% of their US portfolio. Moreover, 1492 Capital Management Llc has 0.27% invested in the company for 30,663 shares. The Wisconsin-based Timpani Capital Management Llc has invested 0.27% in the stock. Great Point Partners Llc, a Connecticut-based fund reported 87,914 shares.#img1#
Ratings analysis reveals 0 of Dipexium Pharmaceuticals’s analysts are positive. Out of 2 Wall Street analysts rating Dipexium Pharmaceuticals, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. DPRX was included in 3 notes of analysts from October 14, 2015. The rating was downgraded by Raymond James on Wednesday, October 26 to “Mkt Perform”. The rating was downgraded by Feltl & Co to “Hold” on Tuesday, October 25. The firm has “Buy” rating given on Wednesday, October 14 by Raymond James.
Dipexium Pharmaceuticals, Inc., incorporated on January 14, 2010, is a late-stage pharmaceutical company. The Firm is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection.
More notable recent Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on March 16, 2014, also Finance.Yahoo.com with their article: “Dipexium Pharmaceuticals Reports Third Quarter 2016 Financial Results” published on November 10, 2016, Prnewswire.com published: “Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results” on August 04, 2016. More interesting news about Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) were released by: Prnewswire.com and their article: “Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in …” published on May 12, 2016 as well as Streetinsider.com‘s news article titled: “Dipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints” with publication date: October 25, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia